Dose-Dependent Effect of Aprotinin on Aggravated Pro-Inflammatory Cytokines in Patients with Pulmonary Hypertension Following Cardiopulmonary Bypass

Cardiovascular Drugs and Therapy

Volumn 17, Issue 4, 2003, Pages 343-348

  Lei, Ye ^a,b   Haider, Husnain Kh ^a   Chusnsheng, Wang ^b   Zhiqiang, Cheng ^b   Hao, Chen ^b   Kejian, Hu ^b   Qiang, Zhao ^b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Cardiopulmonary bypass; Cytokine; Inflammatory response; Pulmonary hypertension

Indexed keywords

APROTININ; BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; INFLAMMATION; LUNG ARTERY PRESSURE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL;

AGED; APROTININ; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; SERINE PROTEINASE INHIBITORS;

EID: 0345491343     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1027399707418     Document Type: Article

References (32)

1. Barrons RW, Jahr JS. A review of post-cardiopulmonary bypass bleeding, amino caproic acid, tranexamic acid and aprotinin. Am J Ther 1996;3(12):821-828.
2. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;8571:1289-1291.
3. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101(6):958-967.
4. Alonso A, Whitten CW, Hill GE. Pump prime only aprotinin inhibits cardiopulmonary bypass induced neutropulmonary hypertensionil CD11b up-regulation. Ann Thorac Surg 1999;67(2):392-395.
5. Asimakopoulos G, Taylor KM, Haskard DO, Iandis RC. Inhibition of neutropulmonary hypertensionil L-selectin shedding: A potential anti-inflammatory effect of aprotinin. Perfusion 2000;15(6):495-499.
6. Hill GE, Whitten CW, Landers DF. The influence of cardiopulmonary bypass on cytokines and cell-cell communication. J Cardiothorac Vasc Anesth 1997;11(3):367-375.
7. Hill GE. Cardiopulmonary bypass-induced inflammation; is it important? J Cardiothorac Vasc Anesth 1998;12(2):21-25.
8. Hattori Y, Kasai K. Induction of mRNAs for ICAM-1, VCAM-1, and ELAM-1 in cultured rat cardiac myocytes and myocardium in vivo. Biochem Mol Biol Int 1997;41(5):979-986.
9. Kacimi R, Karliner JS, Koudssi F, Long CS. Expression and regulation of adhesion molecules in cardiac cells by cytokines, response to acute hypoxia. Circ Res 1998;82(5):576-586.
10. Bando K, Turrentine MW, Sharp TG, et al. Pulmonary hypertension after operations for congenital heart disease: Analysis of risk factors and management. J Thorac Cardiovasc Surg 1996;112(6):1600-1609.
11. Ye Lei, Jiang Zhen, Xia Liming, Hu Kejian. Induction of higher expression of IL-1β and TNF-α, lower expression of IL-10 and cGMP by pulmonary arterial hypertension following cardiopulmonary bypass. Asian J Surgery 2002;25(2):203-208.
12. Mathias MA, Tribble CG, Dietz JF, et al. Aprotinin improves pulmonary function during reperfusion in an isolated lung model. Ann Thorac Surg 2000;70(5):1671-1674.
13. Liu Y, Wang Q, Zhu X, et al. Pulmonary artery perfusion with protective solution reduces lung injury after cardiopulmonary bypass. Ann Thorac Surg 2000;69(5):1402-1407.
14. Defraigne JO, Pincemail J, Larbuisson R, Blaffart F, Limet R. Cytokine release and neutropulmonary hypertensionil activation are not prevented by heparin-coated circuits and aprotinin administration. Ann Thorac Surg 2000(4);69:1084-1091.
15. Kristiansson M, Soop M, Saraste L, Sundqvist KG. Cytokines in stored red blood cell concentrates: Promoters of systemic inflammatory and stimulators of acute transfusion reaction. Acta Anaesthesiol Scand 1996;40(4):496-501.
16. Finn A, Naik S, Klein N, Levinsky RJ, Strobel S, Elliott M. IL-8 release and neutropulmonary hypertensionil degranulation after pediatric cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;105(2):234-241.
17. Drazan KE, Wu L, Bullington D, Shaked A. Viral IL-10 gene therapy inhibits TNF-α and IL-1β, not IL-6, in the newborn endotoxemic mouse. J Pediatr Surg 1996;31(3):411-414.
18. Chaly YV, Paleolog EM, Kolesnikova TS, Tikhonov II, Petratchenko EV, Voitenok NN. Neutropulmonary hypertensionil α-defensin human neutropulmonary hypertensionil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur Cytokine New 2000;11(2):257-266.
19. Bando K, Turrentine MW, Sharp TG, et al. Pulmonary hypertension after operations for congenital heart disease: Analysis of risk factors and management. J Thorac Cardiovasc Surg 1996;112(6):1600-1609.
20. Boldt J, Kumle B, Papsdorf M, Hempelmann G. Are circulating adhesion molecules specially changed in cardiac surgical patients? Ann Thorac Surg 1998;65(3):608-614.
21. Kacimi R, Karliner JS, Koudssi F, Long CS. Expression and regulation of adhesion molecules in cardiac cells by cytokines, response to acute hypoxia. Circ Res 1998;82(5): 576-586.
22. Ohkawa F, Ikeda U, Kanbe T, Kawasaki K, Shimada K. Effects of inflammatory cytokines on vascular tone. Cardiovasc Res 1995;30(5):711-715.
23. Yoshida N, Granger DN, Anderson DC, Rothlein R, Lane C, Kvietys PR. Anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. Am J Physiol 1992;262(6):H1891-1898.
24. Menasche P, Haydar S, Peynet J, et al. A potential mechanism of vasodilation after warm heart surgery: The temperature-dependent release of cytokines. J Thorac Cardiovasc Surg 1994;107(1):293-299.
25. Frering B, Philip I, Dehoux M, Rolland C, Langlois JM, Desmonts JM. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;108(4):636-641.
26. Butler J, Chong GL, Baigrie RJ, Pillai R, Westaby S, Rocker GM. Cytokines response to cardio-pulmonary bypass with membrane and bubble oxygenation. Ann Thorac Surg 1992;53(3):833-838.
27. Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 1996;83(4):696-700.
28. Hill GE, Diego R, Stammers AH, Huffman SM, Pohorecki R. Aprotinin enhances the endogenous release of interleukin 10 after cardiac operation. Ann Thorac Surg 1998;65(1):66-69.
29. Asimakopoulos G, Thompson R, Nourshargh S, et al. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg 2000;120(2):361-369.
30. Asimakopoulos G, Kohn A, Stefanou DC, Haskard DO, landis RC, Taylor KM. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2000;69(4):1192-1197.
31. Wei M, Kuukasjarv P, Laurikka J, et al. Cardioprotective effect of pump prime aprotinin in coronary artery bypass grafting. Cardiovasc Drugs Ther 2002;16(1):37-42.
32. Kalangos A, Tayyareci G, Pretre R, Di Dio P, Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg 1994;8(12):651-656.